This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intelligent and Educational System for Gestational Diabetes Management

This study has been completed.
CIBER-BBN: Networking Research Center for Bioengineering.
Technical University of Madrid
Information provided by (Responsible Party):
Mercedes Rigla, Corporacion Parc Tauli Identifier:
First received: May 3, 2013
Last updated: July 27, 2016
Last verified: July 2016
Gestational diabetes, diabetes diagnosed during pregnancy, affects 8.8% of pregnancies in Spain that means more than 40,000 women per year. This prevalence is based on the National Diabetes Data Group criteria, previous to the 4th workshop on Gestational Diabetes (1998), but, if the new diagnosis criteria proposed by the International Associations of Diabetes and Pregnancy Study Groups, based on the most important study never made before on this topic, prevalence would increase to the double. When a women is diagnosed, the risk of complications for her and the child increases and, therefore, she has to start an specific diet and frequent visits to the diabetes center in order to check that glucose values do not exceed 95 mg/dl before or 140 mg/dl 1-hour after meals. In other case, she should start insulin treatment. Our project is aimed to develop intelligent tools based on neuro-diffuse techniques and integrated in a telemedicine system that allows control of gestational diabetes automatically, guaranteeing glucose control objectives consecution and avoiding face-to-face visits to the health care center. Furthermore, educational and motivation tools for a healthy behaviour will be included. At the end of the study efficacy and security about insulin management will be compare with the recommendations proposed by the diabetes team and data about direct and indirect costs will be calculated. The investigators anticipate that the smart telemedicine system can allow us to detect high blood glucose values earlier than in-person scheduled visits.

Condition Intervention
Gestational Diabetes Other: Smart telemedicine remote monitoring for gestational diabetes Other: Usual management

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care

Further study details as provided by Mercedes Rigla, Corporacion Parc Tauli:

Primary Outcome Measures:
  • Median blood glucose (Interquartile range) [ Time Frame: From inclusion to delivery (estimate average period 10±2 weeks) ]
    Blood glucose data downloaded from the glucometer will allow to obtain the main outcome.

Secondary Outcome Measures:
  • Time from glucose criteria for insulin prescription to actual insulin starting [ Time Frame: From inclusion to delivery From inclusion to delivery (estimate average period 10±2 weeks) ]

Enrollment: 120
Study Start Date: January 2014
Study Completion Date: September 2015
Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Usual management (presential visits)
Patient will follow the usual care program, which includes in-person appointment (weekly/biweekly)
Other: Usual management
Usual care will be provided, including face-to-face visits
Experimental: Smart telemedicine remote monitoring for gestational diabetes
After receiving an structured education on the matter, patients will be followed remotely by analysing glucose and diet/physical activity/other events data with a periodicity no longer than 48 hours
Other: Smart telemedicine remote monitoring for gestational diabetes
Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.

Detailed Description:

This study aims to evaluate the safety and usability of a telemedicine system which includes intelligent tools for blood glucose analysis and supporting routine clinical monitoring carried out by nurses and endocrinologists.

Type of study: Prospective, controlled, randomized (2:1) Participants: pregnant women diagnosed with gestational diabetes according to the National Diabetes Data Group criteria between 14 and 34 weeks of gestation. Patients with suspected clinical diagnosis of type 1 or type 2 diabetes will be excluded.

In addition to the signed acceptance to participate in the study, requirements are:

  • Availability of a desktop computer or laptop with an internet connection and USB port.
  • Sufficient knowledge of Catalan and/or Spanish
  • A mobile phone Objective: To technically evaluate the SineDie telemedicine system and also the users' degree of satisfaction.

Methodology of the study: Once signed consent for participation the patient will be randomized either to continue regularly scheduled visits (33% chance) or to use the Telemedicine system (66% chance). The randomization will be done using a system of allocation based on random numbers. The SINEDiE system includes:

  • Educational Program
  • Automatical Evaluation of glucose data -immediately after each download (frequency not exceeding 72 hours)
  • Alerts in case of failure of receiving information at the scheduled time or in case of incompleteness.
  • Alerts for glucose values higher than desirable but which could be corrected by diet changes and / or exercise
  • Alerts for high glucose values which cannot be corrected with the previous mentioned changes. In this case an appointment for face-to-face visit would be made.

All warnings are also reported as an email to the endocrinologist and nurse


  • Statistical analysis of data: blood glucose, standard deviation, number of preprandial values> 90, the number of postprandial values of> 140 messages and warnings
  • Analytical variables: HbA1c at the start and every 4 weeks
  • Complications of pregnancy and childbirth if any.
  • Neonatal Complications if any
  • Survey of satisfaction with telemedicine tool

Expected duration of the study: 6 months Number of patients included 20 patients


Ages Eligible for Study:   18 Years to 46 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pregnancy; Gestational diabetes diagnosed according the National Diabetes data Group Criteria.

Exclusion Criteria:

  • Pregestational diabetes (diagnosed or suspected); Illiteracy; no computer connected to internet availability; unwillingness to participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01850199

Parc Tauli Sabadell University Hospital
Sabadell, Barcelona, Spain, 08208
Sponsors and Collaborators
Corporacion Parc Tauli
CIBER-BBN: Networking Research Center for Bioengineering.
Technical University of Madrid
  More Information

Responsible Party: Mercedes Rigla, Director, Endocrinology and Nutrition Dpt., Corporacion Parc Tauli Identifier: NCT01850199     History of Changes
Other Study ID Numbers: SINEDiE
Study First Received: May 3, 2013
Last Updated: July 27, 2016

Keywords provided by Mercedes Rigla, Corporacion Parc Tauli:
Gestational diabetes
Artificial Intelligence

Additional relevant MeSH terms:
Diabetes, Gestational
Pregnancy Complications
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on July 19, 2017